SCHEMBL2987160

SCHEMBL2987160

CCCCCC=CP(=O)(O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 2/20 0.55
GGPS1 O95749 1/20 0.55
LPAR1 Q92633 1/20 0.48
LPAR2 Q9HBW0 1/20 0.48
FABP3 P05413 5/20 0.48
FAAH O00519 2/20 0.46
TRPV1 Q8NER1 1/20 0.46
GMNN O75496 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
APEX1 P27695 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18864258 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL18864250 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL2991060 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL4305083 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL11221963 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL18864277 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL18864269 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL2978872 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL18864257 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3
SCHEMBL2988530 0.98 LPAR3 (0.53) LPAR3GGPS1LPAR1LPAR2FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US claimed
US-20100285601-A1 METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-11-11 US claimed
WO-2009041917-A1 METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-04-02 WO claimed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US disclosed
US-20100285601-A1 METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-11-11 US disclosed
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents GENZYME CORPORATION (US) 2010-07-08 US disclosed
US-7678369-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2010-03-16 US disclosed
WO-2009041917-A1 METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-04-02 WO disclosed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents GENZYME CORPORATION (US) 2006-02-09 US disclosed
US-6890523-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2005-05-10 US disclosed
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents GELTEX PHARMACEUTICALS, INC. 2003-07-24 US disclosed
US-6517827-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
US-6517826-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
EP-1189622-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS Geltex Pharmaceuticals, Inc. (US) 2002-03-27 EP disclosed
US-6290946-B1 ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. GELTEX PHARMACEUTICALS, INC. 2001-09-18 US disclosed
WO-2000069428-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GELTEX PHARMACEUTICALS, INC. (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents MSN, ANTXR2, PNKP LPAR3 695/4885GGPS1 2569/4885LPAR1 640/4885
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents DDOST, DNPEP, IDUA LPAR3 907/4885GGPS1 2942/4885LPAR1 845/4885
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents MSN, ANTXR2, PNKP LPAR3 695/4885GGPS1 2569/4885LPAR1 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.